Expansion makes new break-through anticancer therapies closer to home for more Texans
(DALLAS) April 12, 2023 –– Internationally known cancer researcher, Dr. Anthony Tolcher, CEO and founder of NEXT Oncology, continues to increase access to world-class Phase I cancer research and the latest in new agents and anticancer treatments with the opening of NEXT Oncology – Dallas. NEXT Dallas is the organization’s third Texas site and is located at 6750 North MacArthur Boulevard, Suite 250 in Irving.
“Cancer has no geographic boundaries,” said Dr. Tolcher. “One of the continuing challenges has been that cancer research has been conducted in silos. Our goal has always been to break down those barriers and bring potentially life-saving therapies to people in other cities within Texas, while at the same time expediting the development of new therapies for the treatment and eventual cure of cancer.”
NEXT Oncology’s Phase I centers provide patients with advanced cancer who have exhausted conventional treatment options access to the newest cancer treatments available. NEXT Dallas’ clinical director, Dr. Shiraj Sen believes NEXT Oncology is the perfect place to compassionately improve outcomes for patients with cancer, now and in the future.
Dr. Sen, a native Texan, received his undergraduate degree from the University of Texas at Austin and his MD and PhD degrees from the University of Texas at Houston and MD Anderson Cancer Center Graduate School of Biomedical Sciences. His post graduate training in internal medicine was performed at the University of Texas Southwestern Medical Center in Dallas prior to completing his hematology and medical oncology fellowship at the University of Texas MD Anderson Cancer Center.
“Phase I oncology trials are an important step in the drug development process,” Dr. Sen said. “At NEXT Dallas, our team feels fortunate to be able to offer promising new treatment options to individuals with advanced cancer while providing compassionate, personalized care.”
About NEXT Oncology
NEXT Oncology is dedicated to the development of new anticancer agents for patients whose current cancer therapy is no longer working to benefit them and are looking for their next option. NEXT is partnered with Texas Oncology, the largest private oncology practice in the United States with more than 400 referring oncologists and US Oncology, a network of independent, community-based oncologists in the U.S. This formidable size and reach provide NEXT unprecedented opportunities to transform what has come to be expected from clinical trials of new agents.
Contact: Jill Byrd, 210-501-4288